HRP20180289T1 - Spojevi i postupci za inhibiciju antiporta posredovanu s pomoću nhe pri liječenju poremećaja povezanih sa zadržavanjem tekućine ili prevelikom količinom soli i poremećajima gastrointestinalnog trakta - Google Patents

Spojevi i postupci za inhibiciju antiporta posredovanu s pomoću nhe pri liječenju poremećaja povezanih sa zadržavanjem tekućine ili prevelikom količinom soli i poremećajima gastrointestinalnog trakta Download PDF

Info

Publication number
HRP20180289T1
HRP20180289T1 HRP20180289TT HRP20180289T HRP20180289T1 HR P20180289 T1 HRP20180289 T1 HR P20180289T1 HR P20180289T T HRP20180289T T HR P20180289TT HR P20180289 T HRP20180289 T HR P20180289T HR P20180289 T1 HRP20180289 T1 HR P20180289T1
Authority
HR
Croatia
Prior art keywords
image
compound according
treatment
compound
disorderss
Prior art date
Application number
HRP20180289TT
Other languages
English (en)
Inventor
Dominique Charmot
Jeffrey W. Jacobs
Michael Robert Leadbetter
Marc Navre
Chris Carreras
Noah Bell
Original Assignee
Ardelyx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardelyx, Inc. filed Critical Ardelyx, Inc.
Publication of HRP20180289T1 publication Critical patent/HRP20180289T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (11)

1. Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time, da spoj ima sljedeću strukturu (X): Jezgra (L-NHE) n (X) pri čemu: nje 2; NHE ima jednu od sljedećih struktura: [image] ili L je polialkilen glikolni linker; i Jezgra se bira iz skupine koju čine: [image]
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da L je polietilen glikol linker.
3. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time, da je spoj odabran između: [image] [image] [image] [image] [image] [image] [image] ili njegove farmaceutski prihvatljive soli.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time, da je spoj odabran između: [image] [image]
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time, da je spoj odabran između: [image] [image] [image]
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time, da je spoj [image]
7. Farmaceutski pripravak, naznačen time, da sadržava spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegov stereoizomer ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da je namijenjen upotrebi u liječenju sindroma iritabilnog crijeva.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da je namijenjen upotrebi u liječenju krajnjeg stadija bolesti bubrega.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da je namijenjen upotrebi u liječenju kronične bolesti bubrega.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time,da je namijenjen upotrebi u liječenju konstipacije povezane s cističnom fibrozom.
HRP20180289TT 2008-12-31 2018-02-15 Spojevi i postupci za inhibiciju antiporta posredovanu s pomoću nhe pri liječenju poremećaja povezanih sa zadržavanjem tekućine ili prevelikom količinom soli i poremećajima gastrointestinalnog trakta HRP20180289T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14185308P 2008-12-31 2008-12-31
US16950909P 2009-04-15 2009-04-15
US23784209P 2009-08-28 2009-08-28
PCT/US2009/069852 WO2010078449A2 (en) 2008-12-31 2009-12-30 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP09796924.0A EP2384318B1 (en) 2008-12-31 2009-12-30 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Publications (1)

Publication Number Publication Date
HRP20180289T1 true HRP20180289T1 (hr) 2018-03-23

Family

ID=41650053

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180289TT HRP20180289T1 (hr) 2008-12-31 2018-02-15 Spojevi i postupci za inhibiciju antiporta posredovanu s pomoću nhe pri liječenju poremećaja povezanih sa zadržavanjem tekućine ili prevelikom količinom soli i poremećajima gastrointestinalnog trakta

Country Status (22)

Country Link
US (4) US8541448B2 (hr)
EP (3) EP3939964A1 (hr)
JP (2) JP5502106B2 (hr)
KR (5) KR20200111230A (hr)
CN (2) CN102333759A (hr)
AU (1) AU2009334511C1 (hr)
BR (1) BRPI0923861B8 (hr)
CA (1) CA2748607A1 (hr)
CY (1) CY1120451T1 (hr)
DK (1) DK2384318T3 (hr)
ES (1) ES2657938T3 (hr)
HK (1) HK1198162A1 (hr)
HR (1) HRP20180289T1 (hr)
HU (1) HUE036405T2 (hr)
IL (3) IL213852A (hr)
LT (1) LT2384318T (hr)
MX (2) MX345283B (hr)
NO (1) NO2384318T3 (hr)
PL (1) PL2384318T3 (hr)
PT (1) PT2384318T (hr)
SI (1) SI2384318T1 (hr)
WO (1) WO2010078449A2 (hr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2384318T (lt) * 2008-12-31 2018-02-26 Ardelyx, Inc. Junginiai ir būdai, skirti nhe-medijuoto antiporto slopinimui, gydant sutrikimus, susijusius su skysčių kaupimusi ir druskų pertekliumi, bei virškinamojo trakto sutrikimus
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN102757390B (zh) * 2011-04-27 2015-04-22 中国中化股份有限公司 一种制备2-甲氧基-4-肼基-5-氟嘧啶的方法
AU2013304812B2 (en) * 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029984A1 (en) * 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) * 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3988120A1 (en) * 2013-04-12 2022-04-27 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
CA2915633A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
KR20160042039A (ko) * 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
WO2015084158A1 (en) * 2013-12-06 2015-06-11 N.V. Nutricia A pyrimidine derivative and a fatty acid source for use in the treatment of constipation
SG11201700398RA (en) * 2014-07-25 2017-02-27 Taisho Pharmaceutical Co Ltd Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
DE102014019388A1 (de) 2014-12-29 2016-06-30 Susanne Wagner Arzneimittel auf der Basis von Maghämit zur gleichzeitigen Reduzierung der gastrointestinalen Natriumresorption und Phosphatresorption
CN107405505A (zh) * 2015-01-07 2017-11-28 加州生物医学研究所 用于治疗囊性纤维化的化合物
JP6421100B2 (ja) * 2015-09-04 2018-11-07 株式会社ダイセル カルボン酸アミド化合物の製造方法
US10016379B2 (en) * 2015-10-30 2018-07-10 Robin L. Webb Method of treatment for third spacing
JP7292207B2 (ja) * 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
KR20190128626A (ko) * 2017-01-09 2019-11-18 알데릭스, 인코포레이티드 Nhe-매개 역수송의 저해제
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
KR20200074085A (ko) 2017-08-04 2020-06-24 알데릭스, 인코포레이티드 고칼륨혈증 치료를 위한 글리시레틴산 유도체
EP3705471A4 (en) * 2017-11-02 2021-08-11 UBE Industries, Ltd. DOUBLE-HEADED PROTEASE INHIBITOR
WO2019091503A1 (en) 2017-11-13 2019-05-16 Zentiva K.S. Solid forms of tenapanor and method of preparation of tenapanor
CN109897044A (zh) * 2017-12-07 2019-06-18 北京大学 抗神经病理性疼痛化合物及其制备方法
WO2020051014A1 (en) 2018-09-04 2020-03-12 Teva Pharmaceuticals International Gmbh Processes for the preparation of tenapanor and intermediates thereof
CN109321529A (zh) * 2018-10-19 2019-02-12 浙江工商大学 一种体外肠道模型的构建方法和应用
CN114008065A (zh) 2019-02-07 2022-02-01 阿德利克斯股份有限公司 用于治疗高钾血症的甘草次酸衍生物
WO2020181555A1 (zh) * 2019-03-14 2020-09-17 深圳仁泰医药科技有限公司 Nhe3抑制剂的晶型a及其制备方法和应用
JP7194848B2 (ja) 2019-05-16 2022-12-22 イーライ リリー アンド カンパニー ナトリウム－水素交換体３阻害剤化合物
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
CN112679427B (zh) * 2019-10-17 2023-05-12 江苏恒瑞医药股份有限公司 四氢异喹啉类衍生物、其制备方法及其在医药上的应用
CN112047881B (zh) * 2020-10-10 2023-04-11 山东汇海医药化工有限公司 一种坦帕诺的制备方法
IL303799A (en) * 2020-12-18 2023-08-01 Shanghai Jemincare Pharmaceutical Co Ltd TETRAHYDROISOQUINOLINE COMPOUND IN SUBSTITUTE BENZOHETROCYCLE
TW202400583A (zh) * 2022-06-20 2024-01-01 大陸商上海濟煜醫藥科技有限公司 苯並雜環取代四氫異喹啉類化合物鹽型及其製備方法

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926891A (en) 1974-03-13 1975-12-16 Dow Chemical Co Method for making a crosslinkable aqueous solution which is useful to form soft, water-swellable polyacrylate articles
US3997484A (en) 1974-04-03 1976-12-14 The United States Of America As Represented By The Secretary Of Agriculture Highly-absorbent starch-containing polymeric compositions
US3935099A (en) 1974-04-03 1976-01-27 The United States Of America As Represented By The Secretary Of Agriculture Method of reducing water content of emulsions, suspensions, and dispersions with highly absorbent starch-containing polymeric compositions
US4090013A (en) 1975-03-07 1978-05-16 National Starch And Chemical Corp. Absorbent composition of matter
JPS51125468A (en) 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
JPS5346389A (en) 1976-10-07 1978-04-25 Kao Corp Preparation of self-crosslinking polymer of acrylic alkali metal salt
US4190562A (en) 1977-04-04 1980-02-26 The B. F. Goodrich Company Improved water absorbent copolymers of copolymerizable carboxylic acids and acrylic or methacrylic esters
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4286082A (en) 1979-04-06 1981-08-25 Nippon Shokubai Kagaku Kogyo & Co., Ltd. Absorbent resin composition and process for producing same
JPS6025045B2 (ja) 1980-03-19 1985-06-15 製鉄化学工業株式会社 塩水吸収能のすぐれたアクリル酸重合体の製造方法
JPS57158209A (en) 1981-03-25 1982-09-30 Kao Corp Production of bead-form highly water-absorbing polymer
JPS5832607A (ja) 1981-08-20 1983-02-25 Kao Corp 吸水性に優れた吸水材料の製造法
US4985518A (en) 1981-10-26 1991-01-15 American Colloid Company Process for preparing water-absorbing resins
JPS6187702A (ja) 1984-10-05 1986-05-06 Seitetsu Kagaku Co Ltd 吸水性樹脂の製造方法
US4708997A (en) 1985-07-22 1987-11-24 The Dow Chemical Company Suspending agent for the suspension polymerization of water-soluble monomers
US4806532A (en) 1985-10-08 1989-02-21 Mayo Foundation For Medical Education And Research Inhibition of epithelial phosphate transport
DE3544770A1 (de) 1985-12-18 1987-06-19 Stockhausen Chem Fab Gmbh Verfahren und vorrichtung zum kontinuierlichen herstellen von polymerisaten und copolymerisaten der acrylsaeure und/oder methacrylsaeure
US4766004A (en) 1986-12-19 1988-08-23 Warner-Lambert Company Crunchy, highly palatable, bulk-increasing, dietary fiber supplement composition
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
US4999200A (en) 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
US5149541A (en) 1988-10-03 1992-09-22 The Procter & Gamble Company Psyllium-containing produces with a distribution of particle size
US5145906A (en) 1989-09-28 1992-09-08 Hoechst Celanese Corporation Super-absorbent polymer having improved absorbency properties
US5126150A (en) 1990-10-01 1992-06-30 The Procter & Gamble Company Compositions containing psyllium
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
CA2151741C (en) 1991-12-30 2001-12-11 Alan Justice Methods of producing analgesia and enhancing opiate analgesia
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
DK0612723T3 (da) 1993-02-20 1998-03-30 Hoechst Ag Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
MX213505B (hr) 1993-02-24 2003-04-03
US5629377A (en) 1993-03-10 1997-05-13 The Dow Chemical Company Water absorbent resin particles of crosslinked carboxyl containing polymers and method of preparation
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US5489670A (en) 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5650222A (en) 1995-01-10 1997-07-22 The Procter & Gamble Company Absorbent foam materials for aqueous fluids made from high internal phase emulsions having very high water-to-oil ratios
DE19518796A1 (de) 1995-05-22 1996-11-28 Hoechst Ag Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2224795C (en) 1995-06-27 2001-04-03 Neurex Corporation Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5550167A (en) 1995-08-30 1996-08-27 The Procter & Gamble Company Absorbent foams made from high internal phase emulsions useful for acquiring aqueous fluids
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
EP0876347B1 (en) 1995-11-24 2005-03-02 GlaxoSmithKline S.p.A. Quinoline derivatives
DE19548812A1 (de) 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
EP0837055A1 (en) 1996-07-30 1998-04-22 Hoechst Aktiengesellschaft Substituted Indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them
DE19633966A1 (de) 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1998011090A2 (en) 1996-09-16 1998-03-19 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines
ES2302350T3 (es) 1997-02-28 2008-07-01 Nycomed Gmbh Combinacion sinergica de inhibidores de pde y agonistas de adenilatociclasa o agonistas de guanililciclasa.
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
KR100219918B1 (ko) 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
DE19849722A1 (de) 1998-10-28 2000-05-04 Aventis Pharma Gmbh Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO2000043402A2 (en) 1999-01-21 2000-07-27 Board Of Regents, The University Of Texas System Inhibitors of intestinal apical membrane na/phosphate co-transportation
US6624150B2 (en) 1999-02-26 2003-09-23 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US6287609B1 (en) 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
PT1196396E (pt) 1999-07-19 2008-05-14 Univ North Carolina Compostos farmacologicamente activos com dois princípios activos covalentemente ligados (bloqueador dos canais do sódio/agonista do receptor p2y2) para o tratamento de superfícies mucosas
CO5190714A1 (es) 1999-07-20 2002-08-29 Smithkline Beecham Corp Inhibidores del transporte de fosfato
US6107356A (en) 1999-08-23 2000-08-22 The Procter & Gamble Company High suction polymeric foam materials
DE19941764A1 (de) * 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
DE19945302A1 (de) 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
ATE275402T1 (de) 1999-11-01 2004-09-15 John Rhodes Arzneimittel zur behandlung von darmverstopfung und reizkolon
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
WO2001064212A1 (en) 2000-03-01 2001-09-07 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
DE10015248A1 (de) 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
US20030212074A1 (en) 2000-05-02 2003-11-13 Dimitri Gaitanopoulos Phosphate transport inhibitors
JP2003533477A (ja) 2000-05-12 2003-11-11 スミスクライン・ビーチャム・コーポレイション リン酸輸送阻害剤
DE10043667A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
AU2002213048A1 (en) 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
JP2004517066A (ja) 2000-11-20 2004-06-10 ダウ グローバル テクノロジーズ インコーポレイティド 水吸収性ポリマーの生体内での使用
DE10063294A1 (de) 2000-12-19 2002-07-04 Aventis Pharma Gmbh Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PT1379224E (pt) 2001-03-29 2009-10-22 Synergy Pharmaceuticals Inc Agonistas do receptor da guanilato ciclase para o tratamento de inflamação de tecidos e carcinogénese
US6736705B2 (en) 2001-04-27 2004-05-18 Hitachi Global Storage Technologies Polishing process for glass or ceramic disks used in disk drive data storage devices
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
JP2007131532A (ja) 2001-09-28 2007-05-31 Kirin Brewery Co Ltd 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
UA77042C2 (en) * 2001-12-05 2006-10-16 Sanofi Aventis Deutschland Substituted 4-tetrahydroquinolines, use thereof as medicament, a medicament containing them
WO2003048134A1 (fr) 2001-12-05 2003-06-12 Japan Tobacco Inc. Compose de triazole et son utilisation therapeutique
DE10161767A1 (de) 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10163992A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
EP1485078B1 (en) 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
DE60307799T2 (de) 2002-03-19 2007-08-16 Genzyme Corp., Cambridge Hemmer des phosphattransports
US20050176746A1 (en) 2002-05-17 2005-08-11 Frank Weber Use of compounds that are effective as selective opiate receptor modulators
US7014862B2 (en) 2002-05-20 2006-03-21 The Procter & Gamble Company Chewable compositions containing a gel-forming extract of psyllium
TWI245308B (en) 2002-09-13 2005-12-11 Getters Spa Non-evaporable getter compositions which can be reactivated at low temperature after exposure to reactive gases at a higher temperature
CN1254051C (zh) 2002-10-25 2006-04-26 华为技术有限公司 城域网传输设备中用户数据业务子速率传送方法
US6923466B2 (en) 2002-12-17 2005-08-02 James Tsai Collapsible handcart capable of extending the area of carrier by operating handle
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US7026303B2 (en) 2003-02-18 2006-04-11 The Procter & Gamble Company Compositions comprising a polysaccharide component and one or more coating layers
WO2004085448A2 (en) 2003-03-19 2004-10-07 Genzyme Corporation Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
JP4926473B2 (ja) 2003-03-27 2012-05-09 協和発酵キリン株式会社 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
WO2004113396A1 (ja) 2003-06-25 2004-12-29 Cmet Inc. 安定性の向上した活性エネルギー線硬化性の光学的立体造形用樹脂組成物
WO2005020612A1 (en) 2003-08-20 2005-03-03 Musky Communications (Proprietary) Limited Telephonic communication
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
US20050095578A1 (en) 2003-10-31 2005-05-05 Koller Manfred R. Method and apparatus for cell permeabilization
WO2005054705A2 (en) 2003-11-26 2005-06-16 Brian Judd Apparatus for dampening impact vibration in manual tools
US20050244367A1 (en) 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
WO2005113396A2 (en) 2004-05-14 2005-12-01 Paceco Corp Method and apparatus for making status reporting devices for container handlers
CN1984668A (zh) 2004-05-14 2007-06-20 北卡罗来纳大学查珀尔希尔分校 作为涉及盐和/或体液稳态的疾病的治疗剂和诊断剂的尿鸟苷蛋白原及合成的类似物或自其衍生的蛋白酶解产物
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101040028B (zh) 2004-10-13 2012-03-28 罗利克有限公司 光可交联材料
DE102004054847A1 (de) 2004-11-13 2006-05-24 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
CN101267906B (zh) 2005-08-29 2010-11-03 迪美科技控股有限公司 电动工具
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
AU2006311765A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
JP2009514893A (ja) 2005-11-03 2009-04-09 イリプサ， インコーポレイテッド 多価インドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
US7694181B2 (en) 2005-12-12 2010-04-06 Archivas, Inc. Automated software testing framework
GB0610009D0 (en) 2006-05-19 2006-06-28 Health Prot Agency Culture medium
GB2438389A (en) 2006-05-23 2007-11-28 Gkn Aerospace Transparency Sys Heating system for leading edge of aircraft
WO2008002971A2 (en) 2006-06-29 2008-01-03 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8617903B2 (en) 2007-01-29 2013-12-31 The Invention Science Fund I, Llc Methods for allergen detection
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
WO2008137318A1 (en) 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
LT2384318T (lt) 2008-12-31 2018-02-26 Ardelyx, Inc. Junginiai ir būdai, skirti nhe-medijuoto antiporto slopinimui, gydant sutrikimus, susijusius su skysčių kaupimusi ir druskų pertekliumi, bei virškinamojo trakto sutrikimus

Also Published As

Publication number Publication date
EP2384318A2 (en) 2011-11-09
AU2009334511B2 (en) 2016-01-28
KR20200111230A (ko) 2020-09-28
EP2384318B1 (en) 2017-11-15
LT2384318T (lt) 2018-02-26
US20130274285A1 (en) 2013-10-17
SI2384318T1 (en) 2018-03-30
HUE036405T2 (hu) 2018-07-30
KR20160140994A (ko) 2016-12-07
IL250641B (en) 2018-06-28
US20140107074A1 (en) 2014-04-17
HK1198162A1 (en) 2015-03-13
US8969377B2 (en) 2015-03-03
CN102333759A (zh) 2012-01-25
IL250641A0 (en) 2017-04-30
US20120263670A1 (en) 2012-10-18
IL213852A (en) 2017-02-28
JP2012514009A (ja) 2012-06-21
WO2010078449A3 (en) 2010-09-30
AU2009334511C1 (en) 2016-08-18
US20150190389A1 (en) 2015-07-09
MX345283B (es) 2017-01-24
EP3939964A1 (en) 2022-01-19
MX2011007024A (es) 2011-09-27
IL259851B (en) 2020-07-30
KR101766619B1 (ko) 2017-08-08
CA2748607A1 (en) 2010-07-08
US9006281B2 (en) 2015-04-14
JP5805802B2 (ja) 2015-11-10
CY1120451T1 (el) 2019-07-10
ES2657938T3 (es) 2018-03-07
BRPI0923861A2 (pt) 2015-07-28
WO2010078449A2 (en) 2010-07-08
US8541448B2 (en) 2013-09-24
EP3351248B1 (en) 2021-06-09
BRPI0923861B1 (pt) 2020-03-10
KR20110110287A (ko) 2011-10-06
CN103819403B (zh) 2017-01-04
PT2384318T (pt) 2018-02-07
JP5502106B2 (ja) 2014-05-28
EP3351248A1 (en) 2018-07-25
KR20170091783A (ko) 2017-08-09
JP2014114300A (ja) 2014-06-26
BRPI0923861B8 (pt) 2021-05-25
NO2384318T3 (hr) 2018-04-14
PL2384318T3 (pl) 2018-04-30
IL213852A0 (en) 2011-07-31
CN103819403A (zh) 2014-05-28
US9408840B2 (en) 2016-08-09
KR101683318B1 (ko) 2016-12-07
DK2384318T3 (en) 2018-02-19
KR20220042487A (ko) 2022-04-05
IL259851A (en) 2018-07-31
AU2009334511A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
HRP20180289T1 (hr) Spojevi i postupci za inhibiciju antiporta posredovanu s pomoću nhe pri liječenju poremećaja povezanih sa zadržavanjem tekućine ili prevelikom količinom soli i poremećajima gastrointestinalnog trakta
HRP20171175T1 (hr) Novi triciklički spojevi
JP2015526459A5 (hr)
JP2012514009A5 (hr)
HRP20180591T1 (hr) Inhibitori kinaze serina ili treonina
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
JP2012502037A5 (hr)
JP2014508753A5 (hr)
HRP20140361T1 (hr) Monodisperzne smjese pegiliranog naloksola
HRP20190500T1 (hr) Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina
HRP20161577T1 (hr) Inhibitori replikacije virusa gripe
HRP20161074T1 (hr) Benzoksazolski inhibitori kinaza i postupci njihove upotrebe
HRP20171197T1 (hr) Bifenilsulfonamidni antagonist receptora endotelina i angiotensina ii, namijenjen liječenju glomeruloskleroze
HRP20140103T1 (hr) Izokinolinski modulatori transportera atp-vežuä†e kazete
HRP20161408T1 (hr) Cefalosporin koji sadrži katehol skupinu
HRP20151425T1 (hr) Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe
HRP20140107T1 (hr) Benzodiazepinski inhibitori bromodomene
HRP20150797T1 (hr) Supstituirani derivati ksantina
JP2009537554A5 (hr)
HRP20171384T4 (hr) Farmaceutski pripravak
JP2010077141A5 (hr)
HRP20120957T1 (hr) Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid
FR2906140B1 (fr) Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
JP2014500861A5 (hr)
JP2013542945A5 (hr)